정밀의료 소프트웨어 시장 규모, 점유율과 동향 분석 리포트 : 컴포넌트별, 배포별, 용도별, 기술별, 치료 영역별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Precision Medicine Software Market Summary

The global precision medicine software market size was valued at USD 2.12 billion in 2024 and is projected to reach USD 5.66 billion by 2033, growing at a CAGR of 11.8% from 2025 to 2033. This growth is attributed to declining cost of genome sequencing, rise of targeted and personalized therapies, the increase of decentralized trials, and real-world evidence.

Moreover, government and institutional initiatives supporting genomics and precision medicine, and demand for personalized healthcare, have fueled the industry outlook. The declining cost of genome sequencing has transformed it from a high-cost, research-only tool into a routine part of clinical practice, making it a key driver of the precision medicine software industry. What once cost nearly USD 100 million per genome in the early 2000s can now be performed for under USD 500, enabling widespread adoption by hospitals, diagnostic labs, pharmaceutical companies, and even consumer health firms.

This affordability has led to a surge in large-scale genomic testing, generating massive datasets that require advanced software for storage, integration, and interpretation. Precision medicine software plays a central role in converting this raw sequencing data into actionable clinical insights for diagnosis, therapy selection, and patient stratification, driving demand as sequencing becomes standard in oncology, rare disease treatment, and preventive healthcare.

Global Precision Medicine Software Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global precision medicine software market report based on component, deployment mode, application, technology, therapeutic area, end use and region.

• Component Outlook (Revenue, USD Million, 2021 - 2033)
• Software
• Services
  • Implementation & integration
  • Clinical interpretation & reporting services
  • Validation & regulatory support
  • Data curation / annotation services
  • Others
• Deployment Mode Outlook (Revenue, USD Million, 2021 - 2033)
• Cloud-based
• On-premise
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Genomic Data Management & Analysis
• Multi-omics Analytics
• Clinical Decision Support & Treatment Planning
• Companion Diagnostics & Biomarker Discovery Tools
• Clinical Trial Matching & Site Selection
• Others (Population Genomics / Public-health Precision Tools)
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• AI / Machine Learning models & Generative AI
• Rule-based engines (clinical guidelines, pathways)
• Cloud & Containerized Pipelines (Kubernetes/Docker)
• High-performance compute / HPC for genomics
• Interoperability / FHIR / HL7 integration
• Others (Data lakes & MDM (multi-modal data stores))
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Cardiology
• Neurology / CNS
• Rare & Genetic Disorders
• Infectious Diseases (pathogen genomics)
• Immunology / Autoimmune
• Others (dermatology, endocrinology)
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Pharmaceutical & Biotech companies
• Diagnostic Laboratories & Genomic Service Providers
• Contract Research Organizations (CROs)
• Others (Research Institutes & Academic Centers)
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Component
  • 1.2.2. Deployment Mode
  • 1.2.3. Application
  • 1.2.4. Technology
  • 1.2.5. Therapeutic Area
  • 1.2.6. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Declining Cost of Genome Sequencing
    • 3.2.1.2. Shift toward value-based and personalized care
    • 3.2.1.3. Government and institutional initiatives supporting genomics and precision medicine
    • 3.2.1.4. Rising patient awareness and demand for personalized healthcare
    • 3.2.1.5. Maturing interoperability standards (FHIR, GA4GH, HL7)
    • 3.2.1.6. Advances in AI and machine learning
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High implementation and maintenance costs
    • 3.2.2.2. Integration challenges with legacy electronic health records
    • 3.2.2.3. Shortage of skilled professionals in bioinformatics, genomics, and data science.
  • 3.2.3. Industry Opportunity Analysis
  • 3.2.4. Industry Challenge Analysis
  • 3.2.5. Technology Overview
  • 3.2.6. Case Studies
• 3.3. Business Environment Analysis
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal Landscape

Chapter 4. Precision Medicine Software Market: Component Estimates & Trend Analysis

• 4.1. Component Segment Dashboard
• 4.2. Component Market Share Movement Analysis, 2024 & 2033
• 4.3. Market Size & Forecasts and Trend Analysis, by Component, 2021 to 2033 (USD Million)
• 4.4. Software
  • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Services
  • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Implementation & integration
    • 4.5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Clinical interpretation & reporting services
    • 4.5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.4. Validation & regulatory support
    • 4.5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.5. Data curation / annotation services
    • 4.5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.6. Others
    • 4.5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Precision Medicine Software Market: Deployment Mode Estimates & Trend Analysis

• 5.1. Deployment Mode Dashboard
• 5.2. Deployment Mode Market Share Movement Analysis, 2024 & 2033
• 5.3. Market Size & Forecasts and Trend Analysis, by Deployment Mode, 2021 to 2033 (USD Million)
• 5.4. Cloud Based
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. On-Premise
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Precision Medicine Software Market: Application Estimates & Trend Analysis

• 6.1. Application Segment Dashboard
• 6.2. Application Market Share Movement Analysis, 2024 & 2033
• 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Genomic Data Management & Analysis
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Multi-omics Analytics
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Clinical Decision Support & Treatment Planning
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Companion Diagnostics & Biomarker Discovery Tools
  • 6.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Clinical Trial Matching & Site Selection
  • 6.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.9. Others (Population Genomics / Public-health Precision Tools)
  • 6.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Precision Medicine Software Market: Technology Estimates & Trend Analysis

• 7.1. Technology Dashboard
• 7.2. Technology Market Share Movement Analysis, 2024 & 2033
• 7.3. Market Size & Forecasts and Trend Analysis, by Technology, 2021 to 2033 (USD Million)
• 7.4. AI / Machine Learning models & Generative AI
  • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Rule-based engines (clinical guidelines, pathways)
  • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Cloud & Containerized Pipelines (Kubernetes/Docker)
  • 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. High-performance compute / HPC for genomics
  • 7.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Interoperability / FHIR / HL7 integration
  • 7.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.9. Others (Data lakes & MDM (multi-modal data stores))
  • 7.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Precision Medicine Software Market: Therapeutic Area Estimates & Trend Analysis

• 8.1. Therapeutic Area Dashboard
• 8.2. Therapeutic Area Market Share Movement Analysis, 2024 & 2033
• 8.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)
• 8.4. Oncology
  • 8.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Cardiology
  • 8.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Neurology / CNS
  • 8.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Rare & Genetic Disorders
  • 8.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8. Infectious Diseases (pathogen genomics)
  • 8.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.9. Immunology / Autoimmune
  • 8.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.10. Others (dermatology, endocrinology)
  • 8.10.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Precision Medicine Software Market: End Use Estimates & Trend Analysis

• 9.1. End Use Segment Dashboard
• 9.2. End Use Market Share Movement Analysis, 2024 & 2033
• 9.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 9.4. Hospitals
  • 9.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.5. Pharmaceutical & Biotech companies
  • 9.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.6. Diagnostic Laboratories & Genomic Service Providers
  • 9.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.7. Contract Research Organizations (CROs)
  • 9.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.8. Others (Research Institutes & Academic Centers)
  • 9.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Precision Medicine Software Market: Regional Estimates & Trend Analysis

• 10.1. Regional Market Dashboard
• 10.2. Regional Market: Key Takeaways
• 10.3. North America
  • 10.3.1. North America Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.3.2. U.S.
    • 10.3.2.1. Key country dynamic
    • 10.3.2.2. Regulatory framework
    • 10.3.2.3. Competitive insights
    • 10.3.2.4. U.S. Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.3.3. Canada
    • 10.3.3.1. Key country dynamic
    • 10.3.3.2. Regulatory framework
    • 10.3.3.3. Competitive insights
    • 10.3.3.4. Canada Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.3.4. Mexico
    • 10.3.4.1. Key country dynamic
    • 10.3.4.2. Regulatory framework
    • 10.3.4.3. Competitive insights
    • 10.3.4.4. Mexico Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
• 10.4. Europe
  • 10.4.1. Europe Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.4.2. Germany
    • 10.4.2.1. Key country dynamic
    • 10.4.2.2. Regulatory framework
    • 10.4.2.3. Competitive insights
    • 10.4.2.4. Germany Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.4.3. UK
    • 10.4.3.1. Key country dynamic
    • 10.4.3.2. Regulatory framework
    • 10.4.3.3. Competitive insights
    • 10.4.3.4. UK Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.4.4. France
    • 10.4.4.1. Key country dynamic
    • 10.4.4.2. Regulatory framework
    • 10.4.4.3. Competitive insights
    • 10.4.4.4. France Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.4.5. Italy
    • 10.4.5.1. Key country dynamic
    • 10.4.5.2. Regulatory framework
    • 10.4.5.3. Competitive insights
    • 10.4.5.4. Italy Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.4.6. Spain
    • 10.4.6.1. Key country dynamic
    • 10.4.6.2. Regulatory framework
    • 10.4.6.3. Competitive insights
    • 10.4.6.4. Spain Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.4.7. Denmark
    • 10.4.7.1. Key country dynamic
    • 10.4.7.2. Regulatory framework
    • 10.4.7.3. Competitive insights
    • 10.4.7.4. Denmark Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.4.8. Sweden
    • 10.4.8.1. Key country dynamic
    • 10.4.8.2. Regulatory framework
    • 10.4.8.3. Competitive insights
    • 10.4.8.4. Sweden Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.4.9. Norway
    • 10.4.9.1. Key country dynamic
    • 10.4.9.2. Regulatory framework
    • 10.4.9.3. Competitive insights
    • 10.4.9.4. Norway Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
• 10.5. Asia Pacific
  • 10.5.1. Asia Pacific Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.5.2. Japan
    • 10.5.2.1. Key country dynamic
    • 10.5.2.2. Regulatory framework
    • 10.5.2.3. Competitive insights
    • 10.5.2.4. Japan Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.5.3. China
    • 10.5.3.1. Key country dynamic
    • 10.5.3.2. Regulatory framework
    • 10.5.3.3. Competitive insights
    • 10.5.3.4. China Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.5.4. India
    • 10.5.4.1. Key country dynamic
    • 10.5.4.2. Regulatory framework
    • 10.5.4.3. Competitive insights
    • 10.5.4.4. India Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.5.5. South Korea
    • 10.5.5.1. Key country dynamic
    • 10.5.5.2. Regulatory framework
    • 10.5.5.3. Competitive insights
    • 10.5.5.4. South Korea Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.5.6. Australia
    • 10.5.6.1. Key country dynamic
    • 10.5.6.2. Regulatory framework
    • 10.5.6.3. Competitive insights
    • 10.5.6.4. Australia Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.5.7. Thailand
    • 10.5.7.1. Key country dynamic
    • 10.5.7.2. Regulatory framework
    • 10.5.7.3. Competitive insights
    • 10.5.7.4. Thailand Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
• 10.6. Latin America
  • 10.6.1. Latin America Precision Medicine Software Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.6.2. Brazil
    • 10.6.2.1. Key country dynamic
    • 10.6.2.2. Regulatory framework
    • 10.6.2.3. Competitive insights
    • 10.6.2.4. Brazil Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.6.3. Argentina
    • 10.6.3.1. Key country dynamic
    • 10.6.3.2. Regulatory framework
    • 10.6.3.3. Competitive insights
    • 10.6.3.4. Argentina Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
• 10.7. MEA
  • 10.7.1. MEA Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.7.2. South Africa
    • 10.7.2.1. Key country dynamic
    • 10.7.2.2. Regulatory framework
    • 10.7.2.3. Competitive insights
    • 10.7.2.4. South Africa Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.7.3. Saudi Arabia
    • 10.7.3.1. Key country dynamic
    • 10.7.3.2. Regulatory framework
    • 10.7.3.3. Competitive insights
    • 10.7.3.4. Saudi Arabia Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.7.4. UAE
    • 10.7.4.1. Key country dynamic
    • 10.7.4.2. Regulatory framework
    • 10.7.4.3. Competitive insights
    • 10.7.4.4. UAE Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 10.7.5. Kuwait
    • 10.7.5.1. Key country dynamic
    • 10.7.5.2. Regulatory framework
    • 10.7.5.3. Competitive insights
    • 10.7.5.4. Kuwait Precision Medicine Software market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Participant Overview
• 11.2. Company Market Position Analysis/Company Market Share Analysis, (2024)
• 11.3. Company Categorization
• 11.4. Strategy Mapping
• 11.5. Company Profiles/Listing
  • 11.5.1. OSP
    • 11.5.1.1. Overview
    • 11.5.1.2. Financial performance
    • 11.5.1.3. Product benchmarking
    • 11.5.1.4. Strategic initiatives
  • 11.5.2. Genomind
    • 11.5.2.1. Overview
    • 11.5.2.2. Financial performance
    • 11.5.2.3. Product benchmarking
    • 11.5.2.4. Strategic initiatives
  • 11.5.3. IQVIA
    • 11.5.3.1. Overview
    • 11.5.3.2. Financial performance
    • 11.5.3.3. Product benchmarking
    • 11.5.3.4. Strategic initiatives
  • 11.5.4. Genedata AG
    • 11.5.4.1. Overview
    • 11.5.4.2. Financial performance
    • 11.5.4.3. Product benchmarking
    • 11.5.4.4. Strategic initiatives
  • 11.5.5. SOPHiA GENETICS
    • 11.5.5.1. Overview
    • 11.5.5.2. Financial performance
    • 11.5.5.3. Product benchmarking
    • 11.5.5.4. Strategic initiatives
  • 11.5.6. Tempus AI, Inc.
    • 11.5.6.1. Overview
    • 11.5.6.2. Financial performance
    • 11.5.6.3. Product benchmarking
    • 11.5.6.4. Strategic initiatives
  • 11.5.7. Owkin, Inc.
    • 11.5.7.1. Overview
    • 11.5.7.2. Financial performance
    • 11.5.7.3. Product benchmarking
    • 11.5.7.4. Strategic initiatives
  • 11.5.8. Syapse (acquired by N-Power in January 2025)
    • 11.5.8.1. Overview
    • 11.5.8.2. Financial performance
    • 11.5.8.3. Product benchmarking
    • 11.5.8.4. Strategic initiatives
  • 11.5.9. Inspirata, Inc.
    • 11.5.9.1. Overview
    • 11.5.9.2. Financial performance
    • 11.5.9.3. Product benchmarking
    • 11.5.9.4. Strategic initiatives
  • 11.5.10. Precision Medicine Group, LLC.
    • 11.5.10.1. Overview
    • 11.5.10.2. Financial performance
    • 11.5.10.3. Product benchmarking
    • 11.5.10.4. Strategic initiatives
  • 11.5.11. Siemens
    • 11.5.11.1. Overview
    • 11.5.11.2. Financial performance
    • 11.5.11.3. Product benchmarking
    • 11.5.11.4. Strategic initiatives
  • 11.5.12. GenomOncology LLC
    • 11.5.12.1. Overview
    • 11.5.12.2. Financial performance
    • 11.5.12.3. Product benchmarking
    • 11.5.12.4. Strategic initiatives
  • 11.5.13. Qserve
    • 11.5.13.1. Overview
    • 11.5.13.2. Financial performance
    • 11.5.13.3. Product benchmarking
    • 11.5.13.4. Strategic initiatives
  • 11.5.14. Foundation Medicine, Inc.
    • 11.5.14.1. Overview
    • 11.5.14.2. Financial performance
    • 11.5.14.3. Product benchmarking
    • 11.5.14.4. Strategic initiatives
  • 11.5.15. PierianDx
    • 11.5.15.1. Overview
    • 11.5.15.2. Financial performance
    • 11.5.15.3. Product benchmarking
    • 11.5.15.4. Strategic initiatives